Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6962800 | 1.00 | TACR2 (0.73) | TACR2TACR1 | |
| Hydrochloric Acid SCHEMBL9008721 | 0.99 | TACR2 (0.72) | TACR2TACR1 | |
| Hydrochloric Acid SCHEMBL9008725 | 0.99 | TACR2 (0.72) | TACR2TACR1 | |
| SCHEMBL4876940 | 0.92 | TACR2 (0.73) | TACR2 | |
| SCHEMBL4876928 | 0.92 | TACR2 (0.73) | TACR2 | |
| Hydrochloric Acid SCHEMBL9008705 | 0.91 | TACR2 (0.72) | TACR2 | |
| SCHEMBL8291341 | 0.89 | TACR2 (0.74) | TACR2 | |
| Hydrochloric Acid SCHEMBL7049392 | 0.89 | TACR2 (0.71) | TACR2TACR1 | |
| Hydrochloric Acid SCHEMBL7049396 | 0.89 | TACR2 (0.71) | TACR2TACR1 | |
| Hydrochloric Acid SCHEMBL9008693 | 0.89 | TACR2 (0.73) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | claimed |
| US-7368461-B2 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| EP-1444220-B1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | TACR1, TACR2, BDKRB1 | TACR2 2/4885TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.